197 related articles for article (PubMed ID: 28419121)
1. The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements.
Char JE; Dunn C; Davies Z; Milla C; Moss RB; Wine JJ
PLoS One; 2017; 12(4):e0175486. PubMed ID: 28419121
[TBL] [Abstract][Full Text] [Related]
2. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor.
Char JE; Wolfe MH; Cho HJ; Park IH; Jeong JH; Frisbee E; Dunn C; Davies Z; Milla C; Moss RB; Thomas EA; Wine JJ
PLoS One; 2014; 9(2):e88564. PubMed ID: 24520399
[TBL] [Abstract][Full Text] [Related]
3. Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults.
Kim J; Farahmand M; Dunn C; Milla CE; Horii RI; Thomas EAC; Moss RB; Wine JJ
Sci Rep; 2018 Nov; 8(1):16233. PubMed ID: 30389955
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
5. Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.
Kim J; Davies Z; Dunn C; Wine JJ; Milla C
J Cyst Fibros; 2018 Mar; 17(2):179-185. PubMed ID: 29279204
[TBL] [Abstract][Full Text] [Related]
6. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
Yu YC; Sohma Y; Hwang TC
J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
[TBL] [Abstract][Full Text] [Related]
7. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
8. In vivo readout of CFTR function: ratiometric measurement of CFTR-dependent secretion by individual, identifiable human sweat glands.
Wine JJ; Char JE; Chen J; Cho HJ; Dunn C; Frisbee E; Joo NS; Milla C; Modlin SE; Park IH; Thomas EA; Tran KV; Verma R; Wolfe MH
PLoS One; 2013; 8(10):e77114. PubMed ID: 24204751
[TBL] [Abstract][Full Text] [Related]
9. Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.
Abou Alaiwa MH; Launspach JL; Grogan B; Carter S; Zabner J; Stoltz DA; Singh PK; McKone EF; Welsh MJ
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089726
[TBL] [Abstract][Full Text] [Related]
10. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
[TBL] [Abstract][Full Text] [Related]
11. Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T - a case report.
Welsner M; Straßburg S; Taube C; Sutharsan S
BMC Pulm Med; 2019 Apr; 19(1):76. PubMed ID: 30975115
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
13. A simplified cyclic adenosine monophosphate-mediated sweat rate test for quantitative measure of cystic fibrosis transmembrane regulator (CFTR) function.
Callen A; Diener-West M; Zeitlin PL; Rubenstein RC
J Pediatr; 2000 Dec; 137(6):849-55. PubMed ID: 11113843
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl
Wang Y; Cai Z; Gosling M; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L846-L857. PubMed ID: 30136610
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for lumacaftor/ivacaftor clinical response.
Masson A; Schneider-Futschik EK; Baatallah N; Nguyen-Khoa T; Girodon E; Hatton A; Flament T; Le Bourgeois M; Chedevergne F; Bailly C; Kyrilli S; Achimastos D; Hinzpeter A; Edelman A; Sermet-Gaudelus I
J Cyst Fibros; 2019 May; 18(3):368-374. PubMed ID: 30595473
[TBL] [Abstract][Full Text] [Related]
17. Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor.
Mesbahi M; Shteinberg M; Wilschanski M; Hatton A; Nguyen-Khoa T; Friedman H; Cohen M; Escabasse V; Le Bourgeois M; Lucidi V; Sermet-Gaudelus I; Bassinet L; Livnat G
J Cyst Fibros; 2017 Jan; 16(1):45-48. PubMed ID: 27659740
[TBL] [Abstract][Full Text] [Related]
18. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
19. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
20. R117H-CFTR function and response to VX-770 correlate with mRNA and protein expression in intestinal organoids.
Van Mourik P; van Haaren P; Kruisselbrink E; Korkmaz C; Janssens HM; de Winter-de Groot KM; van der Ent CK; Hagemeijer MC; Beekman JM
J Cyst Fibros; 2020 Sep; 19(5):728-732. PubMed ID: 32061518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]